Dennis R Goulet
Overview
Explore the profile of Dennis R Goulet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goulet D, Yan Y, Agrawal P, Waight A, Mak A, Zhu Y
J Comput Biol
. 2022 Jun;
30(1):70-81.
PMID: 35727687
Codon optimization of a DNA sequence can significantly increase efficiency of protein expression, reducing the cost to manufacture biologic pharmaceuticals. Although directed methods based on such factors as codon usage...
2.
Tsai T, Khalili J, Gilchrist M, Waight A, Cohen D, Zhuo S, et al.
Antiviral Res
. 2022 Mar;
199:105271.
PMID: 35240221
COVID-19, an infectious disease caused by the SARS-CoV-2 virus, emerged globally in early 2020 and has remained a serious public health issue. To date, although several preventative vaccines have been...
3.
Goulet D, Chatterjee S, Lee W, Waight A, Zhu Y, Mak A
Antibodies (Basel)
. 2022 Jan;
11(1).
PMID: 35076451
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase whose proliferative effects can contribute to the development of many types of solid tumors when overexpressed. For this reason,...
4.
Chiu M, Goulet D, Teplyakov A, Gilliland G
Antibodies (Basel)
. 2019 Dec;
8(4).
PMID: 31816964
Antibodies and antibody-derived macromolecules have established themselves as the mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure-function relationships of antibodies provides a platform for protein engineering that...
5.
Goulet D, Zwolak A, Williams J, Chiu M, Atkins W
Proteins
. 2019 Nov;
88(5):689-697.
PMID: 31702857
Monoclonal antibodies (mAbs) have become an important class of therapeutics, particularly in the realm of anticancer immunotherapy. While the two antigen-binding fragments (Fabs) of an mAb allow for high-avidity binding...
6.
Goulet D, Atkins W
J Pharm Sci
. 2019 Jun;
109(1):74-103.
PMID: 31173761
Antibody-based proteins have become an important class of biologic therapeutics, due in large part to the stability, specificity, and adaptability of the antibody framework. Indeed, antibodies not only have the...
7.
Goulet D, Watson M, Tam S, Zwolak A, Chiu M, Atkins W, et al.
Drug Metab Dispos
. 2018 Sep;
46(12):1900-1907.
PMID: 30232177
The serum half-life and clearance of therapeutic monoclonal antibodies (mAbs) are critical factors that impact their efficacy and optimal dosing regimen. The pH-dependent binding of an mAb to the neonatal...
8.
Goulet D, Orcutt S, Zwolak A, Rispens T, Labrijn A, de Jong R, et al.
J Biol Chem
. 2017 Nov;
293(2):651-661.
PMID: 29150443
Bispecific antibodies (bsAbs) combine the antigen specificities of two distinct Abs and demonstrate therapeutic promise based on novel mechanisms of action. Among the many platforms for creating bsAbs, controlled Fab-arm...
9.
Zwolak A, Leettola C, Tam S, Goulet D, Derebe M, Pardinas J, et al.
Sci Rep
. 2017 Nov;
7(1):15521.
PMID: 29138497
Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives are critical for therapeutic programs. Here, we identify 3 mutations (T307P, L309Q, and Q311R or "TLQ") in the...
10.
Zwolak A, Armstrong A, Tam S, Pardinas J, Goulet D, Zheng S, et al.
MAbs
. 2017 Sep;
9(8):1306-1316.
PMID: 28898162
The increased number of bispecific antibodies (BsAb) under therapeutic development has resulted in a need for mouse surrogate BsAbs. Here, we describe a one-step method for generating highly pure mouse...